122 related articles for article (PubMed ID: 15346061)
1. Telomerase reverse transcriptase subunit expression is associated with chondrosarcoma malignancy.
Martin JA; DeYoung BR; Gitelis S; Weydert JA; Klingelhutz AJ; Kurriger G; Buckwalter JA
Clin Orthop Relat Res; 2004 Sep; (426):117-24. PubMed ID: 15346061
[TBL] [Abstract][Full Text] [Related]
2. Malignant transformation in human chondrosarcoma cells supported by telomerase activation and tumor suppressor inactivation.
Martin JA; Forest E; Block JA; Klingelhutz AJ; Whited B; Gitelis S; Wilkey A; Buckwalter JA
Cell Growth Differ; 2002 Sep; 13(9):397-407. PubMed ID: 12354749
[TBL] [Abstract][Full Text] [Related]
3. Chondrosarcoma is not characterized by detectable telomerase activity.
Bovée JV; van Den Broek LJ; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2001 Mar; 193(3):354-60. PubMed ID: 11241416
[TBL] [Abstract][Full Text] [Related]
4. Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone.
Horvai AE; Kramer MJ; Garcia JJ; O'Donnell RJ
Mod Pathol; 2008 Apr; 21(4):423-30. PubMed ID: 18204433
[TBL] [Abstract][Full Text] [Related]
5. Differentiation and proliferative activity in benign and malignant cartilage tumors of bone.
Hasegawa T; Seki K; Yang P; Hirose T; Hizawa K; Wada T; Wakabayashi J
Hum Pathol; 1995 Aug; 26(8):838-45. PubMed ID: 7543439
[TBL] [Abstract][Full Text] [Related]
6. Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis.
Liang X; Wang D; Wang Y; Zhou Z; Zhang J; Li J
Diagn Pathol; 2012 Jul; 7():84. PubMed ID: 22809428
[TBL] [Abstract][Full Text] [Related]
7. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
Takeuchi A; Yamamoto Y; Tsuneyama K; Cheng C; Yonekura H; Watanabe T; Shimizu K; Tomita K; Yamamoto H; Tsuchiya H
Cancer; 2007 Jun; 109(12):2532-40. PubMed ID: 17497647
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.
Matsuura S; Oda Y; Matono H; Izumi T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2010 Mar; 41(3):343-51. PubMed ID: 19896699
[TBL] [Abstract][Full Text] [Related]
9. Chondroid Tumors as Incidental Findings and Differential Diagnosis between Enchondromas and Low-grade Chondrosarcomas.
Afonso PD; Isaac A; Villagrán JM
Semin Musculoskelet Radiol; 2019 Feb; 23(1):3-18. PubMed ID: 30699449
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors.
Kalinski T; Sel S; Kouznetsova I; Röpke M; Roessner A
Pathol Res Pract; 2009; 205(5):339-45. PubMed ID: 19157720
[TBL] [Abstract][Full Text] [Related]
11. Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma.
Berend KR; Toth AP; Harrelson JM; Layfield LJ; Hey LA; Scully SP
J Bone Joint Surg Am; 1998 Jan; 80(1):11-7. PubMed ID: 9469303
[TBL] [Abstract][Full Text] [Related]
12. Nicotinamide Phosphoribosyl Transferase Is Increased in Osteosarcomas and Chondrosarcomas Compared to Benign Bone and Cartilage.
Meram AT; Alzubaidi Y; Cotelingam J; Ghali G; Lopez L; Coppola D; Shackelford R
Anticancer Res; 2019 Apr; 39(4):1761-1765. PubMed ID: 30952715
[TBL] [Abstract][Full Text] [Related]
13. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas.
Kawashima A; Okada Y; Nakanishi I; Ueda Y; Iwata K; Roessner A
Gen Diagn Pathol; 1997 Feb; 142(3-4):129-37. PubMed ID: 9065576
[TBL] [Abstract][Full Text] [Related]
14. The oncogene LRF is a survival factor in chondrosarcoma and contributes to tumor malignancy and drug resistance.
Kumari R; Li H; Haudenschild DR; Fierro F; Carlson CS; Overn P; Gupta L; Gupta K; Nolta J; Yik JH; Di Cesare PE
Carcinogenesis; 2012 Nov; 33(11):2076-83. PubMed ID: 22847180
[TBL] [Abstract][Full Text] [Related]
15. Gadd45β expression in chondrosarcoma: a pilot study for diagnostic and biological implications in histological grading.
Zenmyo M; Tanimoto A; Sakakima H; Yokouchi M; Nagano S; Yamamoto T; Ishido Y; Komiya S; Ijiri K
Diagn Pathol; 2010 Oct; 5():69. PubMed ID: 20942912
[TBL] [Abstract][Full Text] [Related]
16. Array-comparative genomic hybridization of central chondrosarcoma: identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations.
Rozeman LB; Szuhai K; Schrage YM; Rosenberg C; Tanke HJ; Taminiau AH; Cleton-Jansen AM; Bovée JV; Hogendoorn PC
Cancer; 2006 Jul; 107(2):380-8. PubMed ID: 16779802
[TBL] [Abstract][Full Text] [Related]
17. Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells.
Sogawa K; Yamada T; Funamoto Y; Kohno K; Nishikawa H; Kishida F; Hamazaki F; Yamashita N; Matsumoto K
Res Commun Mol Pathol Pharmacol; 1994 Dec; 86(3):375-8. PubMed ID: 7712113
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of cytofluorometric DNA ploidy analysis in distinguishing benign cartilaginous tumors from chondrosarcomas.
Kusuzaki K; Murata H; Takeshita H; Hirata M; Hashiguchi S; Tsuji Y; Nakamura S; Ashihara T; Hirasawa Y
Mod Pathol; 1999 Sep; 12(9):863-72. PubMed ID: 10496594
[TBL] [Abstract][Full Text] [Related]
19. hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality.
Lin Y; Seger N; Chen Y; Hesla AC; Wejde J; Ghaderi M; Tsagkozis P; Larsson O; Haglund F
Mod Pathol; 2018 Dec; 31(12):1834-1841. PubMed ID: 30065261
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry for human telomerase reverse transcriptase catalytic subunit (hTERT): a study of 143 benign and malignant soft tissue and bone tumours.
Patel RM; Folpe AL
Pathology; 2009; 41(6):527-32. PubMed ID: 19900100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
